4.7 Article

CAG Expansion in the Huntington Disease Gene Is Associated with a Specific and Targetable Predisposing Haplogroup

期刊

AMERICAN JOURNAL OF HUMAN GENETICS
卷 84, 期 3, 页码 351-366

出版社

CELL PRESS
DOI: 10.1016/j.ajhg.2009.02.003

关键词

-

资金

  1. Canadian Genetic Diseases Network (CGDN)
  2. Huntington Society of Canada (HSC)
  3. Michael Smith Foundation for Health Research (MSFHR)
  4. Canadian Institutes of Health Research (CIHR)
  5. Child and Family Research Institute (CFRI)
  6. HDSA/High Q Foundation

向作者/读者索取更多资源

Huntington disease (HD) is an autosomal-dominant disorder that results from >36 CAG repeats in the HD gene (HTT). Approximately 10% of patients inherit a chromosome that underwent CAG expansion from an unaffected parent with <36 CAG repeats. This study is a comprehensive analysis of genetic diversity in HTTand reveals that HD patients of European origin (n = 65) have a significant enrichment (95%) of a specific set of 22 tagging single nucleotide polymorphisms (SNPs) that constitute a single haplogroup. The disease association of many SNPs is much stronger than any previously reported polymorphism and was confirmed in a replication cohort (n = 203). Importantly, the same haplogroup is also significantly enriched (83%) in individuals with 27-35 CAG repeats (intermediate alleles, n = 66), who are unaffected by the disease, but have increased CAG tract sizes relative to the general Population (n = 116). These data Support a stepwise model for CAG expansion into the affected range (>36 CAG) and identifies specific haplogroup variants in the general population associated with this instability. The specific variants at risk for CAG expansion are not present in the general population in China, Japan, and Nigeria where the prevalence of I ID is much lower. The current data argue that cis-elements have a major predisposing influence on CAG Instability in HTT. The strong association between specific SNP alleles and CAG expansion also provides an opportunity of personalized therapeutics in HD where the clinical development of only a small number of allele-specific targets may be sufficient to treat up to 88% of the HD patient population.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据